Imagine this: a child struggling with attention deficit hyperactivity disorder (ADHD) finally finds some relief through medication, only to stop taking it way sooner than expected. That's the startling reality for underweight kids, according to a groundbreaking study from the University of Gothenburg. But here's where it gets controversial—what if the way we dose these medications is unfairly disadvantaging certain groups? Stick around, because we're about to dive into the details that could change how we think about treating ADHD in children.
First off, let's break down ADHD for anyone new to this. ADHD affects a child's ability to focus, control impulses, and stay still—think of it as a brain that's supercharged with distractions, making everyday tasks like homework or following instructions feel like climbing a mountain. Methylphenidate, a key drug for managing these symptoms, works by helping the brain balance those focus and impulse controls. It's the star ingredient in popular meds like Concerta, Ritalin, and Medikinet, and it's approved for kids as young as six, as well as adults. Simple enough, right? But the study we're talking about uncovers some eye-opening patterns in how this medication is prescribed and why some kids quit early.
This research, published in the journal Pediatric Drugs, looked at 1,741 children and teens who started on methylphenidate. They tracked details like gender, age, body mass index (BMI—that's a measure of body weight relative to height, helping classify kids as underweight, normal weight, overweight, or obese), and medication doses. For 612 of these participants, they even had follow-up info on prescriptions and BMI six to twelve months later. It's like piecing together a puzzle to see how weight plays a bigger role than we might have guessed.
And this is the part most people miss—the dosages reveal stark differences that tie into weight, gender, and age. On the very first prescription, kids with overweight or obesity got slightly higher absolute doses of methylphenidate. But when researchers adjusted for weight—meaning they calculated the dose per kilogram of body weight—those same kids actually received lower weight-adjusted doses. Flip the script for underweight children: their initial doses, when adjusted for weight, turned out to be higher than for heavier peers. Then, at follow-up, absolute dose increases were biggest for obese kids and smallest for underweight ones. Girls, interestingly, ended up with higher doses than boys (both absolute and weight-adjusted), while teens over 12 got higher absolute doses but lower weight-adjusted ones compared to younger kids under 12.
Now, why does this matter so much? Weight, gender, and age aren't just side notes—they're linked to who stops treatment early. Underweight kids are far more likely to discontinue methylphenidate within the first year than those of normal weight. Girls and children over 12 also show higher dropout rates. It's a wake-up call: are we dosing based on one-size-fits-all assumptions, or tailoring it to each child's unique needs? This could be controversial, sparking debates on equity in healthcare. Is it fair that underweight kids might get disproportionately high doses relative to their size, potentially leading to side effects or early quits, while heavier kids get less adjusted dose? Or should we rethink how we calculate these prescriptions to avoid such disparities?
Leading the study, Julia Izsak, a Researcher and Resident in Clinical Pharmacology, and Jenny Kindblom, a Consultant and Professor of Clinical Pharmacology at the University of Gothenburg and Sahlgrenska University Hospital, emphasize the implications. 'There is a significantly higher proportion of children and adolescents with underweight who discontinue treatment during the first year, compared to the group of normal weight,' Izsak notes. 'In addition to this, it is also clear that girls and children over the age of 12 are more likely to discontinue their treatment within a year.'
Their conclusions underscore the urgent need for more studies on how dosing influences both the effectiveness (that's how well the medication works to reduce ADHD symptoms) and safety of methylphenidate for kids and teens, especially across different weight categories. As Izsak puts it, 'There are major gaps in knowledge regarding medicines to children and adolescents. Our results underline the importance of considering children's individual circumstances when starting and monitoring medical treatment for ADHD. Through further research, we hope to increase knowledge and contribute to more accurate treatment strategies for children and adolescents with different weight status.'
If you're curious about related topics, check out these stories: a study on how the biological roots of autism and ADHD might blur diagnostic lines (link: https://www.news-medical.net/news/20251112/Study-Biological-underpinnings-of-autism-and-ADHD-may-transcend-traditional-diagnostic-boundaries.aspx), research showing no link between maternal paracetamol use during pregnancy and ADHD or autism in kids (link: https://www.news-medical.net/news/20251110/Maternal-Paracetamol-use-during-pregnancy-not-linked-to-autism-or-ADHD-in-children.aspx), and an exploration of nutrition paradoxes in Tanzania's 'breadbasket' region (link: https://www.news-medical.net/news/20251111/Unraveling-Tanzaniae28099s-Breadbasket-paradox-in-child-nutrition.aspx).
Source: Izsak, J., et al. (2025). Dosing and Discontinuation of Methylphenidate Medication in Relation to Weight Status in Children and Adolescents. Pediatric Drugs. doi: 10.1007/s40272-025-00728-z. https://link.springer.com/article/10.1007/s40272-025-00728-z
What do you think? Does this study make you question how ADHD meds are prescribed in your community? Do you agree that weight-adjusted dosing could be the key to better outcomes, or is there another factor at play? Share your thoughts in the comments—let's discuss!
